Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Summary
Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them. This bispecific antibody recognizes GD2, a protein found on almost all neuroblastoma and osteosarcoma cells. The investigators put the GD2 bispecific antibody on T cells and give large numbers of these T cells back to patients. The investigators think that these T cells may have a better chance of killing GD2 expressing tumor cells when they are armed with GD2 bispecific antibody. This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neuroblastoma, osteosarcoma, and other GD2-positive solid tumors.
Timeline
- Start
- 2014-11
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD2Bi-aATC | Cell therapy | 4e+07 cells/kg | Intravenous |
| Subject | GD2Bi-aATC | Cell therapy | 8e+07 cells/kg | Intravenous |
| Subject | GD2Bi-aATC | Cell therapy | 1.6e+08 cells/kg | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 300000 iu | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |